Paper36790010
Pseudoprogression versus true progression in glioblastoma: what neurosurgeons need to know.
Young JS and 4 others. J Neurosurg, 2023. Cited by 48 papers, by iCite.
Cite this record
ConductScience Library. Pseudoprogression versus true progression in glioblastoma: what neurosurgeons need to know. Papers, record 36790010. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36790010
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Pseudoprogression versus true progression in glioblastoma: what neurosurgeons need to know.
- PubMed
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Glioblastoma | Major topic |
| Brain Neoplasms | Major topic |
| Humans | |
| Neurosurgeons | |
| Disease Progression | |
| Magnetic Resonance Imaging |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| T32 CA151022 | NCI NIH HHS | United States | T32CA151022 | PubMed and NIH |
Source NIH RePORTER
References79
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 20399573 | Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. | Int J Radiat Oncol Biol Phys | 2011 | https://conductscience.org/library/papers/20399573 | PubMed |
| 2 | 20732762 | Favorable prognosis in patients with high-grade glioma with radiation necrosis: the University of Colorado reoperation series. | Int J Radiat Oncol Biol Phys | 2011 | https://conductscience.org/library/papers/20732762 | PubMed |
| 3 | 31666247 | Clinical Utility of Plasma Cell-Free DNA in Adult Patients with Newly Diagnosed Glioblastoma: A Pilot Prospective Study. | Clin Cancer Res | 2020 | https://conductscience.org/library/papers/31666247 | PubMed |
| 4 | 12234397 | Correlations between magnetic resonance spectroscopy and image-guided histopathology, with special attention to radiation necrosis. | Neurosurgery | 2002 | https://conductscience.org/library/papers/12234397 | PubMed |
| 5 | 33105661 | A Preliminary Study on Machine Learning-Based Evaluation of Static and Dynamic FET-PET for the Detection of Pseudoprogression in Patients with IDH-Wildtype Glioblastoma. | Cancers (Basel) | 2020 | https://conductscience.org/library/papers/33105661 | PubMed |
| 6 | 34594572 | Redo craniotomy or bevacizumab for symptomatic steroid-refractory true or pseudoprogression following IMRT for glioblastoma. | Neurooncol Pract | 2021 | https://conductscience.org/library/papers/34594572 | PubMed |
| 7 | 34899760 | Advanced Imaging Techniques for Differentiating Pseudoprogression and Tumor Recurrence After Immunotherapy for Glioblastoma. | Front Immunol | 2021 | https://conductscience.org/library/papers/34899760 | PubMed |
| 8 | 30627060 | Radiation Necrosis, Pseudoprogression, Pseudoresponse, and Tumor Recurrence: Imaging Challenges for the Evaluation of Treated Gliomas. | Contrast Media Mol Imaging | 2018 | https://conductscience.org/library/papers/30627060 | PubMed |
| 9 | 18452856 | Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. | Lancet Oncol | 2008 | https://conductscience.org/library/papers/18452856 | PubMed |
| 10 | 29590461 | Prognostic value of contrast enhancement and FLAIR for survival in newly diagnosed glioblastoma treated with and without bevacizumab: results from ACRIN 6686. | Neuro Oncol | 2018 | https://conductscience.org/library/papers/29590461 | PubMed |
| 11 | 34297308 | Emerging Technologies for Non-invasive Monitoring of Treatment Response to Immunotherapy for Brain Tumors. | Neuromolecular Med | 2022 | https://conductscience.org/library/papers/34297308 | PubMed |
| 12 | 16517093 | Cerebral radiation necrosis: incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy. | Int J Radiat Oncol Biol Phys | 2006 | https://conductscience.org/library/papers/16517093 | PubMed |
| 13 | 19221865 | Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression. | J Neurooncol | 2009 | https://conductscience.org/library/papers/19221865 | PubMed |
| 14 | 35821676 | Standard clinical approaches and emerging modalities for glioblastoma imaging. | Neurooncol Adv | 2022 | https://conductscience.org/library/papers/35821676 | PubMed |
| 15 | 26545842 | Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. | Lancet Oncol | 2015 | https://conductscience.org/library/papers/26545842 | PubMed |
| 16 | 29390403 | Tumor recurrence versus treatment effects in glioma: A comparative study of three dimensional pseudo-continuous arterial spin labeling and dynamic susceptibility contrast imaging. | Medicine (Baltimore) | 2017 | https://conductscience.org/library/papers/29390403 | PubMed |
| 17 | 33085022 | The histological representativeness of glioblastoma tissue samples. | Acta Neurochir (Wien) | 2021 | https://conductscience.org/library/papers/33085022 | PubMed |
| 18 | 26382848 | Proliferation Index Predicts Survival after Second Craniotomy within 6 Months of Adjuvant Radiotherapy for High-grade Glioma. | Clin Oncol (R Coll Radiol) | 2016 | https://conductscience.org/library/papers/26382848 | PubMed |
| 19 | 31844891 | Toward a standard pathological and molecular characterization of recurrent glioma in adults: a Response Assessment in Neuro-Oncology effort. | Neuro Oncol | 2020 | https://conductscience.org/library/papers/31844891 | PubMed |
| 20 | 19834699 | Distinction between glioma progression and post-radiation change by combined physiologic MR imaging. | Neuroradiology | 2010 | https://conductscience.org/library/papers/19834699 | PubMed |
Cited by46
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 48 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42974199 | Differentiating true progression from pseudoprogression in glioblastomas: Dynamic contrast-enhanced MRI habitat analysis with parsimonious pharmacokinetic model. | Neurooncol Adv | 2026 | https://conductscience.org/library/papers/42974199 | PubMed |
| 42942170 | Threshold-Independent Amide Proton Transfer-Weighted MRI in Post-Treatment Gliomas: A Systematic Review and Meta-Analysis of Effect Size and Diagnostic Accuracy. | Life (Basel) | 2026 | https://conductscience.org/library/papers/42942170 | PubMed |
| 42907136 | Cell-based therapies for malignant glioma. | Stem Cells Transl Med | 2026 | https://conductscience.org/library/papers/42907136 | PubMed |
| 42902051 | Sonolucent cranial windows for bedside ultrasound identification of MRI-concordant glioblastoma recurrence during outpatient surveillance: an imaging correlation pilot study. | Acta Neurochir (Wien) | 2026 | https://conductscience.org/library/papers/42902051 | PubMed |
| 42896233 | Quantitative, longitudinal measurements of response to immunotherapy for glioblastoma using multiparametric MRI in a long-term survivor treated with autologous tumor lysate-loaded dendritic cell vaccine: an illustrative case. | J Neurosurg Case Lessons | 2026 | https://conductscience.org/library/papers/42896233 | PubMed |
| 42829361 | Early experience with cerebrospinal fluid cell-free DNA molecular profiling in a neuro-oncology practice. | J Neurooncol | 2026 | https://conductscience.org/library/papers/42829361 | PubMed |
| 42682614 | Calibrated and explainable multiparametric MRI radiomics for differentiating tumor positive disease from treatment-related changes in glioblastoma. | Front Oncol | 2026 | https://conductscience.org/library/papers/42682614 | PubMed |
| 42396282 | Pembrolizumab, Temozolomide and HSPPC-96 Vaccine in Newly Diagnosed Glioblastoma Post-Chemoradiation: Results from a Multi-institutional, Phase 2, Randomized, Placebo-Controlled Trial. | medRxiv | 2026 | https://conductscience.org/library/papers/42396282 | PubMed |
| 42271271 | Microstructural MRI combined with metabolic MRI to evaluate the progression-free survival of patients with glioblastoma at the early follow-up after tumor treating fields: a pilot study. | BMC Med Imaging | 2026 | https://conductscience.org/library/papers/42271271 | PubMed |
| 42189415 | Peripheral hematological landscapes as biomarkers for detecting postoperative progression in glioblastoma multiforme: a multivariable risk scoring approach. | J Neurooncol | 2026 | https://conductscience.org/library/papers/42189415 | PubMed |
| 42078261 | Neuro-Oncology Biotech Industry Progress Report 2025. | Cureus | 2026 | https://conductscience.org/library/papers/42078261 | PubMed |
| 42016861 | Microfluidic approaches for liquid biopsy in glioblastoma: Insights into diagnostic and follow-up strategies. | Bioeng Transl Med | 2026 | https://conductscience.org/library/papers/42016861 | PubMed |
| 41841145 | Artificial intelligence-based volumetric measurements for longitudinal clinical assessment of treatment response in high-grade gliomas: Validation across institutional and public datasets. | Neurooncol Adv | 2026 | https://conductscience.org/library/papers/41841145 | PubMed |
| 41808979 | Intraosseous Pseudoprogression vs. Progression and Recurrence of Clival Chordoma after Proton Radiation Therapy: Case Series. | J Neurol Surg B Skull Base | 2026 | https://conductscience.org/library/papers/41808979 | PubMed |
| 41803972 | Radiomics in glioblastoma recurrence: advances in prediction, localization, and differentiation from treatment-related effects. | J Transl Med | 2026 | https://conductscience.org/library/papers/41803972 | PubMed |
| 41733867 | Repeat resection for recurrent glioblastoma - does timing matter? | J Neurooncol | 2026 | https://conductscience.org/library/papers/41733867 | PubMed |
| 41677672 | Decoding Glioblastoma Through Liquid Biopsy: Molecular Insights and Clinical Prospects. | Cells | 2026 | https://conductscience.org/library/papers/41677672 | PubMed |
| 41597259 | Advancing Bioconjugated Quantum Dots with Click Chemistry and Artificial Intelligence to Image and Treat Glioblastoma. | Cells | 2026 | https://conductscience.org/library/papers/41597259 | PubMed |
| 41514549 | Timepoint-Specific Benchmarking of Deep Learning Models for Glioblastoma Follow-Up MRI. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/41514549 | PubMed |
| 41289012 | Daily locomotor activity declines with tumor growth and disease progression in glioblastoma. | JCI Insight | 2026 | https://conductscience.org/library/papers/41289012 | PubMed |
Genes5
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ANXA5 | 308 | PubTator's text mining | https://conductscience.org/library/genes/308 | NCBI Gene |
| EGFR | 1956 | PubTator's text mining | https://conductscience.org/library/genes/1956 | NCBI Gene |
| IDH1 | 3417 | PubTator's text mining | https://conductscience.org/library/genes/3417 | NCBI Gene |
| MGMT | 4255 | PubTator's text mining | https://conductscience.org/library/genes/4255 | NCBI Gene |
| TP53 | 7157 | PubTator's text mining | https://conductscience.org/library/genes/7157 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36790010
GET https://conductscience.org/api/papers/v1/36790010/references?page=2